Skip to main content

Table 3 We observed that, as the incorporation size at hexon increased the VP/IP ratio also increased compared to the His6 vectors or unmodified Ad5 .

From: Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach

Modified Viruses Viral Particle (VP) Infectious Particles (IP) VP/IP
Ad5 4.58 × 1012vp/ml 3 × 1011PFU/ml 15.26
Ad/HVR2-His6 5 × 1012vp/ml 3 × 1011PFU/ml 14.7
Ad/HVR5-His6 5 × 1012vp/ml 4 × 1011PFU/ml 14.25
Ad/HVR2-33RGD-His6 4.7 × 1011vp/ml 2 × 109PFU/ml 236
Ad/HVR5-33RGD-His6 1.85 × 1012vp/ml 1.58 × 109PFU/ml 1,170
Ad/HVR5-43RGD-His6 2.35 × 1012vp/ml 3.98 × 108PFU/ml 5,940
Ad/HVR5-53RGD-His6 1.01 × 1012vp/ml 1.25 × 109PFU/ml 808